Suppr超能文献

36 年随访研究:接受与不接受低苯丙氨酸饮食治疗的苯丙酮尿症患者的成本与结局。

Costs and outcomes over 36 years of patients with phenylketonuria who do and do not remain on a phenylalanine-restricted diet.

机构信息

Catalyst Health Economics Consultants, Northwood, UK School of Biomedical Sciences, King's College, London, UK.

出版信息

J Intellect Disabil Res. 2013 Jun;57(6):567-79. doi: 10.1111/j.1365-2788.2012.01568.x. Epub 2012 May 8.

Abstract

BACKGROUND

To quantify the costs and consequences of managing phenylketonuria (PKU) in the UK and to estimate the potential implications to the UK's National Health Service (NHS) of keeping patients on a phenylalanine-restricted diet for life.

METHOD

A computer-based model was constructed depicting the management of PKU patients over the first 36 years of their life, derived from patients suffering from this metabolic disorder in The Health Improvement Network database (a nationally representative database of patients registered with general practitioners in the UK). The model was used to estimate the incidence of co-morbidities and the levels of healthcare resource use and corresponding costs over the 36 years.

RESULTS

Patients who remained on a phenylalanine-restricted diet accounted for 38% of the cohort. Forty-seven per cent of patients discontinued their phenylalanine-restricted diet between 15 and 25 years of age. Of these, 73% remained off diet and 27% restarted a restricted diet at a mean 30 years of age. Fifteen per cent of the cohort had untreated PKU. Eleven per cent of patients who remained on a phenylalanine-restricted diet for 36 years received the optimum amount of prescribed amino acid supplements. Patients had a mean 12 general practitioner visits per year and one hospital outpatient visit annually, but phenylalanine levels were only measured once every 18 to 24 months. The mean NHS cost (at 2007/08 prices) of managing a PKU sufferer over the first 36 years of their life was estimated to range between £21 000 and £149 000, depending on the amount of prescribed nutrition they received.

CONCLUSION

The findings suggest that the majority of patients with PKU were under-treated. The NHS cost of patient management should not be an obstacle to encouraging patients to remain on a restricted diet until further information becomes available about the long-term clinical impact of stopping such a diet. Nevertheless, patients require counselling and managed follow up regardless of the choices they make about their diet.

摘要

背景

定量管理苯丙酮尿症(PKU)在英国的成本和后果,并估计将患者终生限制苯丙氨酸饮食对英国国家医疗服务体系(NHS)的潜在影响。

方法

基于计算机的模型构建,描绘了 PKU 患者在其生命的前 36 年中的管理情况,该模型源自患有这种代谢紊乱的患者,来自于英国健康改善网络数据库(一个全国性的代表英国全科医生注册患者的数据库)。该模型用于估计 36 年内合并症的发病率以及医疗资源的使用水平和相应的成本。

结果

继续限制苯丙氨酸饮食的患者占队列的 38%。47%的患者在 15 至 25 岁之间停止限制苯丙氨酸饮食。其中,73%的患者不再限制饮食,27%的患者在平均 30 岁时重新开始限制饮食。15%的队列患有未经治疗的 PKU。11%的继续限制苯丙氨酸饮食 36 年的患者接受了最佳量的处方氨基酸补充剂。患者平均每年接受 12 次全科医生就诊和每年一次的医院门诊就诊,但苯丙氨酸水平仅每 18 至 24 个月测量一次。管理 PKU 患者前 36 年的 NHS 成本(以 2007/08 年的价格计算)估计在 21000 英镑至 149000 英镑之间,具体取决于他们接受的规定营养量。

结论

这些发现表明,大多数 PKU 患者的治疗不足。在进一步了解停止这种饮食对长期临床影响的信息之前,不应该将患者管理的 NHS 成本作为鼓励患者继续限制饮食的障碍。然而,无论患者对饮食做出何种选择,他们都需要接受咨询和管理随访。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验